Prothena Corporation plc
Prothena Corporation Public Limited Company is a late-stage clinical company engaged in the protein dysregulation and a pipeline of investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.
Buy US stocks in Australia starting with PRTA. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PRTA
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.